Colgate-Palmolive (CL) traded higher Wednesday, up roughly 3% with the stock around $88.93, as the market continued to digest the company’s first-quarter 2026 report released Friday, May 1. The quarter topped expectations on both profit and revenue, and investors focused on management maintaining its full-year outlook despite a tougher cost and category-growth backdrop. (marketbeat.com)

For Q1 2026, Colgate reported net sales of $5.324 billion (+8.4% year over year) and base-business EPS of $0.97, up from $0.91 a year ago, supported by a mix of volume and pricing as well as a meaningful foreign-exchange tailwind. The company reiterated 2026 guidance for net sales growth of 2% to 6% and organic sales growth of 1% to 4%, while updating gross margin expectations lower than previously due to a more challenging cost environment. (files.quartr.com)

Beyond the headline beat, attention centered on continued momentum in international divisions and Hill’s Pet Nutrition, alongside an updated multi-year productivity roadmap. Colgate said its board approved an expansion of the Strategic Growth and Productivity Program (SGPP), lifting estimated cumulative pretax charges to $350 million to $550 million (from $200 million to $300 million) and projecting $200 million to $300 million of annual pretax savings once projects are implemented—framing a longer runway for self-funded brand investment and cost offsets. (files.quartr.com)

The near-term debate is whether Colgate can protect profitability while category growth remains slower and North America is soft, even as emerging markets and pet nutrition carry more of the load. Investors will also track how quickly SGPP actions translate into realized savings versus upfront charges, and whether pricing and volume stay in balance as promotional intensity and input-cost volatility evolve through 2026. (files.quartr.com)